15 August, 2020

First Nifedipine Finished-product Preparation in Palestine for the Treatment of Anal Fissures

Ramallah, August 15, 2020 – Transmed Pharma launched today Antrolin (Nifedipine-Lidocaine cream), the only registered finished-product preparation with Nifedipine that effectively and safely treats anal fissures and proctologies generally associated with anal sphincter. Pharmacy-compounded ointments of Nifedipine have existed for some time in the Palestinian market, however, in different concentrations, under no quality standards or regulatory oversight, and with a short shelf-life.

The efficacy and safety of Antrolin has been tested and proven in a series of controlled, randomized multicenter clinical studied. As a topical treatment, Antrolin is noninvasive and is highly effective in the treatment of chronic anal fishers and in some cases, it spares patients the risk, pain and recovery associated with the surgical interventions. Antrolin is manufactured under strict GMP standards by NewFaDem in Italy and is marketed and distributed in many countries around the world including Georgia, Italy and Lebanon.

About NewFaDem
NewFaDem is an Italian pharmaceutical manufacturing company with deep and strong roots in the industry. The company’s history goes back to the last century in Naples, when in 1939 “Laboratorio Farmaceutico De Meo” started to manufacture the castor oil. Today NewFaDem, driven by its long history and experience, strives to develop specialized therapies with the aim of improving the health and wellness of individuals through scientific research and continuous innovation.

NewFaDem manufacturing facility is spread over 3,000 square meters, equipped with state-of-the-art technology and backed by a qualified workforce in the pharmaceutical science and research. The company employes the highest work and quality standards in all aspects of its manufacturing operations. There are two companies in the NewFaDem SRL corporate family.

Please click here for more information.